FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | GlaxoSmithKline | Cervarix

Glaxo wins European contract for Cervarix

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

GlaxoSmithKline has won another European contract for the cervical cancer vaccine Cervarix. The Dutch government selected Cervarix for a new program to vaccinate all girls aged 12 with a catch-up program for girls aged 13 to 16 in the second half of 2009. In the first year some 350,000 Dutch girls will get the jab.

Cervarix won out over Merck's Gardasil in the Netherlands, but has yet to be approved in the United States. That makes European market penetration vital for Glaxo.

"We are delighted with this decision and the fact that since Cervarix received European approval it has been selected as the cervical cancer vaccine for more than half of eligible tenders across Europe," said Eddie Gray, president of Pharmaceuticals Europe for GSK. "We look forward to working with the Netherlands Vaccine Institute." Globally, cervical cancer is the second leading cause of cancer death among women.

- check out GSK's release

Related Articles:
Glaxo ready to wait for late-stage Cervarix data
UK health officials in cancer vaccine fight
Cervarix data demonstrates prolonged protection

More stories about Vaccine   GlaxoSmithKline   Cervarix  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 19 + 36?
To combat spam, please solve the math question above.